Search results for "MUTATION"

showing 10 items of 2830 documents

Relationship between within-host fitness and virulence in the vesicular stomatitis virus: correlation with partial decoupling.

2012

ABSTRACT Given the parasitic nature of viruses, it is sometimes assumed that rates of viral replication and dissemination within hosts (within-host fitness) correlate with virulence. However, there is currently little empirical evidence supporting this principle. To test this, we quantified the fitness and virulence of 21 single- or double-nucleotide mutants of the vesicular stomatitis virus in baby hamster kidney cells (BHK-21). We found that, overall, these two traits correlated positively, but significant outliers were identified. Particularly, a single mutation in the conserved C terminus of the N nucleocapsid (U1323A) had a strongly deleterious fitness effect but did not alter or even …

ImmunologyMutantVirulenceApoptosisBiologymedicine.disease_causeVirus ReplicationMicrobiologyVesicular stomatitis Indiana virusCell Line03 medical and health sciencesVesicular StomatitisMiceVirologyCricetinaemedicineBaby hamster kidney cellAnimals030304 developmental biologyGlycoproteinsGenetics0303 health sciencesMutationMice Inbred BALB CVirulence030302 biochemistry & molecular biologyCell MembraneBrainNucleocapsid Proteinsbiology.organism_classification3. Good healthProtein Structure TertiaryViral replicationGenetic Diversity and EvolutionVesicular stomatitis virusInsect ScienceMutationFemaleNeuron deathVesicular StomatitisJournal of virology
researchProduct

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

2005

Activating mutations in the FLT3 tyrosine kinase (TK) occur in approximately 35% of patients with acute myeloid leukemia (AML). Therefore, targeting mutated FLT3 is an attractive therapeutic strategy, and early clinical trials testing FLT3 TK inhibitors (TKI) showed measurable clinical responses. Most of these responses were transient; however, in a subset of patients blast recurrence was preceded by an interval of prolonged remission. The etiology of clinical resistance to FLT3-TKI in AML is unclear but is of major significance for the development of future therapeutic strategies. We searched for mechanisms of resistance in 6 patients with AML who had relapses upon PKC412 treatment. In an …

ImmunologyMutation MissenseBiologyBiochemistrychemistry.chemical_compoundIn vivoRecurrencehemic and lymphatic diseasesHumansProtein Kinase InhibitorsProtein Kinase CQuizartinibKinaseMyeloid leukemiaCell BiologyHematologyProtein-Tyrosine KinasesStaurosporineEnzyme ActivationProtein kinase domainchemistryfms-Like Tyrosine Kinase 3Drug Resistance NeoplasmLeukemia MyeloidFms-Like Tyrosine Kinase 3Acute DiseaseCancer researchTyrosine kinaseCrenolanibBlood
researchProduct

Molecular basis of filamin a-filGAP interaction and its impairment in congenital disorders associated with filamin a mutations

2008

Background Mutations in filamin A (FLNa), an essential cytoskeletal protein with multiple binding partners, cause developmental anomalies in humans. Methodology/Principal Findings We determined the structure of the 23rd Ig repeat of FLNa (IgFLNa23) that interacts with FilGAP, a Rac-specific GTPase-activating protein and regulator of cell polarity and movement, and the effect of the three disease-related mutations on this interaction. A combination of NMR structural analysis and in silico modeling revealed the structural interface details between the C and D β-strands of the IgFLNa23 and the C-terminal 32 residues of FilGAP. Mutagenesis of the predicted key interface residues confirmed the b…

ImmunoprecipitationFilaminsMolecular Sequence Dataeducationlcsh:MedicineComputational Biology/Protein Structure PredictionBiologyFilaminCell Biology/Cell SignalingCongenital AbnormalitiesBiochemistry/Protein Folding03 medical and health sciences0302 clinical medicineProtein structureContractile ProteinsCell Biology/CytoskeletonFLNAHumansFLNBFLNCAmino Acid Sequencelcsh:Science030304 developmental biologyGenetics0303 health sciencesMultidisciplinaryBinding SitesMolecular StructureSequence Homology Amino AcidPoint mutationlcsh:RGTPase-Activating ProteinsMicrofilament Proteins3. Good healthBiochemistry/BioinformaticsMutationProtein foldinglcsh:Q118 Biological sciences030217 neurology & neurosurgeryResearch Article
researchProduct

Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study

2019

Ataluren was reported to suppress nonsense mutations by promoting the readthrough of premature stop codons, although its mechanism of action (MOA) is still debated. The likely interaction of Ataluren with CFTR-mRNA has been previously studied by molecular dynamics. In this work we extended the modeling of Ataluren's MOA by complementary computational approaches such as induced fit docking (IFD), quantum polarized ligand docking (QPLD), MM-GBSA free-energy calculations, and computational mutagenesis. In addition to CFTR-mRNA, this study considered other model targets implicated in the translation process, such as eukaryotic rRNA 18S, prokaryotic rRNA 16S, and eukaryotic Release Factor 1 (eRF…

In silicoNonsense mutationComputational biology01 natural sciencesRibosomeBiochemistrychemistry.chemical_compoundDrug DiscoveryQPLDcomputational mutagenesiMM-GBSA010405 organic chemistryChemistryDrug Discovery3003 Pharmaceutical ScienceOrganic Chemistrypremature termination codonSettore CHIM/06 - Chimica OrganicaSettore CHIM/08 - Chimica FarmaceuticaStop codon0104 chemical sciencesAtalurenInduced fit docking010404 medicinal & biomolecular chemistrySettore BIO/18 - GeneticaDocking (molecular)ProofreadingRelease factoroxadiazole
researchProduct

TERT promoter mutation subtypes in 20 in-situ melanomas

2019

In situCancer ResearchSkin NeoplasmsDermatologyBiologyPrognosisMolecular biologyOncologyMutationBiomarkers TumorHumansTert promoter mutationPromoter Regions GeneticMelanomaTelomeraseCarcinoma in SituMelanoma Research
researchProduct

Automated simultaneous triple dissolution profiles of two drugs, sulphamethoxazole-trimethoprim and hydrochlorothiazide-captopril in solid oral dosag…

2003

This article deals with the simultaneous determination of three dissolution profiles with the aid of the new and emerging continuous-flow methodology known as multicommutation. This methodology is based on a flow network of a set of solenoid valves controlled by the computer and acting as independent multicommutators to allow the easy and automated control of flowing solutions. The obtained three dissolution profiles from one dosage form are the whole formulation profile or "global profile" recommended by pharmacopoeias, and, at same time, are recorded two "individual" profiles from two drugs present in the formulation. This is the second attempt to obtain simultaneously three dissolution p…

In vitro availabilityCaptoprilStereochemistryClinical BiochemistryDissolution profilesPharmaceutical ScienceAdministration OralDerivativeTrimethoprimDosage formAnalytical ChemistryHydrochlorothiazideSpectrophotometryQUIMICA ANALITICADrug DiscoveryTrimethoprim Sulfamethoxazole Drug CombinationmedicineSolenoid valves multicommutationDissolutionSpectroscopyAntibacterial agentDosage FormsChromatographymedicine.diagnostic_testChemistryCaptoprilHydrochlorothiazideFlow (mathematics)SolubilityPharmaceuticalsSpectrophotometry UltravioletSulphamethoxazolemedicine.drugJournal of pharmaceutical and biomedical analysis
researchProduct

Geldanamycin and its derivatives as Hsp90 inhibitors

2012

The Hsp90 molecule, one of the most abundant heat shock proteins in mammalian cells, maintains homeostasis and prevents stress-induced cellular damage. Hsp90 is expressed under normal conditions at a level of about 1-2 Percent of total proteins, while its expression increases 2-10 fold in cancer cells. The two main constitutively expressed isoforms of Hsp90 are known as Hsp90-alpha and Hsp90-beta, and their upregulation is associated with tumor progression, invasion and formation of metastases, as well as development of drug resistance. The Hsp90 is a key target for many newly established, potent anticancer agents containing Hsp90 N-terminal ATP binding inhibitors, such as geldanamycin, and…

IndolesLactams MacrocyclicCyclin-Dependent KinaseAntineoplastic AgentsTanespimycinBenzoquinoneModels BiologicalAntineoplastic Agentchemistry.chemical_compoundDownregulation and upregulationTransforming Growth Factor betaCyclin-dependent kinaseHeat shock proteinBenzoquinonespolycyclic compoundsAnimalsHumansHSP90 Heat-Shock ProteinsbiologyAnimalTriazolesGeldanamycinHsp90Cyclin-Dependent KinasesProto-Oncogene Proteins c-rafHSP90 Heat-Shock Proteinsrc-Family KinaseschemistryTumor progressionMutationCancer cellbiology.proteinCancer researchMacrolidesMacrolideTriazoleTumor Suppressor Protein p53Animals; Antineoplastic Agents; Benzoquinones; Cyclin-Dependent Kinases; HSP90 Heat-Shock Proteins; Humans; Lactams Macrocyclic; Macrolides; Models Biological; Mutation; Novobiocin; Proto-Oncogene Proteins c-raf; Transforming Growth Factor beta; Triazoles; Tumor Suppressor Protein p53; src-Family KinasesNovobiocinHumanFrontiers in Bioscience
researchProduct

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)…

2015

Abstract Background: Luspatercept is a fusion protein (modified activin receptor IIB-IgG Fc) being investigated for the treatment of anemias with ineffective erythropoiesis. MDS patients have increased Smad2/3 signaling in the bone marrow, leading to ineffective erythropoiesis. Luspatercept inhibits Smad2/3 signaling and promotes late-stage erythroid differentiation, thereby correcting ineffective erythropoiesis. Aims: This completed, 3-month, phase 2, multicenter, open-label study evaluated the effects of luspatercept on anemia in patients with low/int-1 risk MDS (IPSS classification). Study outcomes include erythroid response of increased hemoglobin (Hb) in low transfusion burden (LTB) pa…

Ineffective erythropoiesisOncologymedicine.medical_specialtyAnemiaImmunologyPopulationGene mutationmedicine.disease_causeLower riskBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineMedicineeducationLenalidomideeducation.field_of_studybusiness.industryMyelodysplastic syndromesCell BiologyHematologymedicine.disease3. Good healthSurgery030220 oncology & carcinogenesisAbsolute neutrophil countbusiness030215 immunologymedicine.drugBlood
researchProduct

CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders

2013

International audience; BACKGROUND:The high frequency of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene mutation p.Arg117His in patients with congenital bilateral absence of the vas deferens (CBAVD) and in newborns screened for CF has created a dilemma.METHODS:Phenotypic and genotypic data were retrospectively collected in 179 non-newborn French individuals carrying p.Arg117His and a second CFTR mutation referred for symptoms or family history, by all French molecular genetics laboratories, referring physicians, CF care centres and infertility clinics.RESULTS:97% of the patients had the intronic T7 normal variant in cis with p.Arg117His. 89% patients were male, wit…

InfertilityMalemedicine.medical_specialtyHeterozygoteCystic FibrosisOffspring[SDV]Life Sciences [q-bio]Cystic Fibrosis Transmembrane Conductance RegulatorGene mutationCompound heterozygosityAsymptomaticCystic fibrosis03 medical and health sciences0302 clinical medicineVas DeferensMale Urogenital DiseasesMutation RateInternal medicinePrenatal DiagnosisGenotypeGeneticsmedicineHumansFamily historyChildSweatGenetics (clinical)Infertility Male030304 developmental biology0303 health sciencesbusiness.industryInfant NewbornInfantmedicine.disease3. Good healthPhenotype030228 respiratory systemChild PreschoolImmunologyMutationFemalemedicine.symptombusiness
researchProduct

A branch and bound algorithm for the matrix bandwidth minimization

2008

In this article, we first review previous exact approaches as well as theoretical contributions for the problem of reducing the bandwidth of a matrix. This problem consists of finding a permutation of the rows and columns of a given matrix which keeps the non-zero elements in a band that is as close as possible to the main diagonal. This NP-complete problem can also be formulated as a labeling of vertices on a graph, where edges are the non-zero elements of the corresponding symmetrical matrix. We propose a new branch and bound algorithm and new expressions for known lower bounds for this problem. Empirical results with a collection of previously reported instances indicate that the propose…

Information Systems and ManagementDegree matrixBand matrixGeneral Computer ScienceBranch and boundBlock matrixManagement Science and Operations ResearchPermutation matrixIndustrial and Manufacturing EngineeringCombinatoricsModeling and SimulationCuthill–McKee algorithmDiagonal matrixMathematicsSparse matrixEuropean Journal of Operational Research
researchProduct